Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Inlyta
(United States) [Available]Synonyms :
axitinib
Class :
Anticancer & protein kinase inhibitors
Brand Name :
Inlyta
(United States) [Available]Synonyms :
axitinib
Class :
Anticancer & protein kinase inhibitors
Dosage Forms & Strengths
Oral tablet
1 mg
5 mg
Advanced renal cancer
First line therapy:
5
mg
twice a day
every 12 hrs in combination with avelumab, increase to 7 mg after 2 weeks toleration.
Reduce the dose to 3-2 mg if adverse effects appear.
5 mg twice a day every 12 hrs, in combination with pembrolizumab, increase to 7 mg after 6 weeks of toleration.
Reduce the dose to 3-2 mg if adverse effects appear.
Second-line therapy:
5 mg twice a day every 12 hrs, increase to 7 mg after 6 weeks of tolerance. Reduce the dose to 3-2 mg if adverse effects appear.
5
mg
Orally
twice a day
every 12hrs, on an empty stomach, increase to 7 mg after 6 weeks of toleration.
Reduce the dose to 3-2 mg if adverse effects appear.
Safety and efficacy are not established
Refer to adult dosing
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with axitinib
hepatic enzyme metabolism i.e., CYP3A4 metabolism is affected when lidocaine used combinely with axitinib and raising its levels
nafcillin will decrease the effect of action of axitinib by affecting enzyme CYP3A4 metabolism.
the effect of axitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased effect of axitinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
axitinib increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased risk of adverse effect
CYP3A strong enhancers of the small intestine may reduce the bioavailability of axitinib
the interaction may enhance the hypertensive effect
the interaction may increase the active metabolite serum concentration of artesunate
axitinib may increase the cardiotoxic and hepatotoxic effects of avelumab
the interaction with axitinib may enhance the risk of osteonecrosis
may increase the serum level of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may enhance the serum levels of CYP3A4 substrates
may enhance the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
axitinib may increase the hepatotoxic effects of pembrolizumab
may increase the hypertension effects of solriamfetol
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serum when combined with axitinib
Combining tegafur with axitinib can reduce tegafur’s metabolism
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
When dexrabeprazole and axitinib is used together, this leads to reduction in the dexrabeprazole’s metabolism
When axitinib is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
axitinib When axitinib is used together with somatotropin, this leads to a rise in axitinib ‘s metabolism
When axitinib is used together with ouabain, this leads to reduction in axitinib excretion
When axitinib is used together with allylestrenol, this leads to a reduction in the axitinib metabolism
When axitinib is used together with oleandomycin, this leads to enhanced concentration serum of axitinib
When axitinib is used together with patupilone, this leads to enhanced concentration serum of axitinib
When axitinib is used together with ridaforolimus, this leads to enhanced concentration serum of axitinib
axitinib: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
when combined with axitinib, the metabolism of ramosetron may be reduced
the metabolism of axitinib may experience a decrease when combined with danoprevir
When axitinib is used together with adenine, this leads to a reduction in the axitinib's metabolism
the concentration of axitinib in the bloodstream can be raised when combined with filgotinib
when both drugs combine axitinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
Docetaxel may increase the serum level of axitinib by affecting the enzyme CYP3A4
the rate of excretion of axitinib may be reduced
the risk of gastrointestinal or other bleeding may be increased
Action and spectrum:
Action:
VEGFR-1,2 and 3 are signals which are blocked by tyrosine kinase inhibitor axitinib which stops the progression of cancer.
Frequency defined
>40-20%
Hypertension (40%)
Decreased serum bicarbonate (44%)
Hyperglycemia (28%)
Weight loss (25%)
>10%
Decreased white blood cell count (11%)
Dyspnea (15%)
1-10%
Arterial thrombosis (2%)
Pulmonary embolism (2%)
Alopecia (4%)
Upper abdominal pain (8%)
Frequency not defined
Melena
Cerebral hemorrhage
Retinal artery occlusion
Contraindication/Caution:
Due to potential risks people with severe liver illness, cardiac patients, allergic reactions, or following surgery shouldn’t use axitinib.
Pregnancy Warnings:
Pregnancy category: C
Lactation:
Excretion of the drug into human breast milk is unknown
Pregnancy Categories:
Pharmacology
It exhibits high potency and selectivity for its target kinase. The compound has been specifically developed to limit its activity only to non-kinase targets to some degree.
Pharmacodynamics
This drug activates the receptor tyrosine kinase and stops the signaling cascades and helps in apoptosis.
Pharmacokinetics:
Absorption
It is rapidly absorbed.
Distribution
It is distributed rapidly in blood streams.
Metabolism
It metabolizes the drug through liver enzymes.
Excretion and Elimination
half-life of 2.5 to 6 hours.
Administration:
The route of administration is oral
Patient Information Leaflet
Generic Name: axitinib
Pronounced: axIT-i-nib
Why do we use axitinib?
An oral VEGFR and kinase inhibitor called axitinib is used to treat advanced renal cell carcinoma after a previous systemic therapy has failed.
It is used in kidney cell cancer and investigated for treatment in pancreatic and thyroid cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
